Why the study?
Does TCV-116 or enalapril reduce tissue mRNA levels of TGF-beta 1 and extracellular matrix components in DOCA-salt hypertensive rats?
Does TCV-116 or enalapril reduce tissue mRNA levels of TGF-beta 1 and extracellular matrix components in DOCA-salt hypertensive rats?
Angiotensin II receptor antagonism or ACE inhibition reduces renal injury and fibrotic gene expression in DOCA-salt hypertensive rats independent of blood pressure lowering.
Answers are grounded in this paper and cite their sources.
Supports BP-independent renoprotection by ARB/ACEI in hypertensive rats; leaves open translation to human CKD.
To investigate the role of angiotensin II (Ang II) in hypertension-induced tissue injury, we gave TCV-116 (1 mg/kg per day PO), a nonpeptide Ang II type I receptor antagonist, or enalapril (10 mg/kg per day PO) to deoxycorticosterone acetate (DOCA)-salt hypertensive rats for 3 weeks and examined the effects on tissue mRNA levels for transforming growth factor-beta 1 (TGF-beta 1) and extracellular matrix components. Tissue mRNA levels were measured by Northern blot analysis. Renal mRNA levels for TGF-beta 1; types I, III, and IV collagen; and fibronectin in DOCA-salt hypertensive rats were increased by severalfold (P < .01) compared with sham-operated rats. In the aorta of DOCA-salt hypertensive rats, TGF-beta 1 and fibronectin mRNA levels were increased, but types I, III, and IV collagen mRNAs did not increase. In the heart, increased mRNA was found only for fibronectin. Thus, these gene expressions are regulated in a tissue-specific manner. TCV-116 or enalapril did not lower blood pressure in DOCA-salt hypertensive rats. However, the increase in renal mRNAs for TGF-beta 1 and extracellular matrix components in DOCA-salt hypertensive rats was significantly inhibited by treatment with TCV-116 or enalapril, which was associated with a significant decrease in urinary protein and albumin excretions and histological improvement of renal lesions. In contrast, in the aorta and heart these gene expressions were not affected by TCV-116 or enalapril. Thus, local Ang II may contribute to renal injury of DOCA-salt hypertension by stimulating the gene expression of TGF-beta 1 and extracellular matrix components.
No takes yet. Share an insight, caveat, or question.
Kim et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: